NEW YORK — Tasso said on Wednesday that it has received CE marking for its Tasso-M20 self-sampling blood collection device.
The device is designed for the at-home collection, storage, and transport of four dried blood samples for laboratory processing. Tasso said it offers shipping and logistics support for product customers.
The device is for the collection of blood samples for clinical trials, and according to the Seattle-based firm, the Tasso-M20 was designed for the collection, storage, and transport of samples for analyzing drug levels or monitoring biomarkers that include small molecules, proteins, antibodies, or nucleic acids.
In late 2020, Tasso said that it intends to seek Emergency Use Authorization from the US Food and Drug Administration for an at-home blood sampling device for SARS-CoV-2 testing. Earlier that year, the company raised $17 million in Series A funding.